Challenge to ABO blood type barrier in living donor liver transplantation

• 作者: Hiroto Egawa
• 来源期刊: 国际肝胆胰疾病杂志(英文版)
• 年，卷（期）: 2020,（4）
• 页码范围: 342-348
• 页数: 7页
• 语种: 英文

摘要

ABO incompatible living donor liver transplantation has the potential to expand the donor pool for pa- tients with end stage liver diseases on the expense of challenges to overcome immunological barriers across blood type. There is a profound impact of age on incidence and severity of antibody mediated rejection (AMR). Even children older than 1 year have chances of AMR; children aged 8 years or older have risks of hepatic necrosis similar to adult liver recipients. The mechanism of AMR is based on cir- culatory disturbances secondary to inflammation and injury of the vascular endothelium caused by an antibody-antigen-complement reaction. The strategy to overcome ABO blood type barrier is based on both pre-transplant desensitization and adequate treatment of this phenomenon. Nowadays, rituximab is the standard means of desensitization but unfortunately an insufficient aid to treat AMR. Because of low inci- dence (less than 5％ in the rituximab era), in practice of AMR only some case reports about the treatment of clinical AMR are available in the literature. Initial experiences revealed that the proteasome inhibitor, bortezomib might be a promising treatment based on its capacity to deplete plasma cell agents. Although ABO blood type barrier has been counteracted in 95％ of patients by applying "rituximab-desensitization", many issues, such as prediction of high-risk patients of infection and AMR and secure treatment strate- gies for evoked AMR, remain to be resolved.